StageZero Life Sciences Ltd (SZLSF) Predicción del precio de las acciones

StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 40 full-time employees. The company is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The firm offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.